Lentiviral gene transfer vectors and their medicinal applications

Patent metadata

Field	Value
Publication number	US-9328146-B2
Application number	US-201414197532-A
Country	US
Kind code	B2
Filing date	Mar 5, 2014
Priority date	Aug 3, 2007
Publication date	May 3, 2016
Grant date	May 3, 2016

Abstract

The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors can be either integrative or non-integrative vectors. The invention encompasses prophylactic, therapeutic, symptomatic, and curative treatments of animals, including humans, as well as gene therapy and vaccination in vivo.

First claim

The invention claimed is:

1. A lentiviral vector particle comprising a nucleic acid comprising a functional lentiviral DNA flap sequence;
wherein the lentiviral vector particle is pseudotyped with a vesicular stomatitis virus G protein selected from New Jersey, SVCV, Isfahan, and Cocal strains, and
wherein the vesicular stomatitis virus G protein is generated in human cells from a nucleic acid sequence that has been codon-optimized for expression in human cells.

2. The lentiviral vector particle of claim 1 , wherein the vesicular stomatitis virus G protein is of the New Jersey strain.

3. The lentiviral vector particle of claim 1 , wherein the vesicular stomatitis virus G protein is of the SVCV strain.

4. The lentiviral vector particle of claim 1 , wherein the vesicular stomatitis virus G protein is of the Isfahan strain.

5. The lentiviral vector particle of claim 1 , wherein the vesicular stomatitis virus G protein is of the Cocal strain.

6. The lentiviral vector particle of claim 1 , wherein the lentiviral vector particle encodes at least one human immunodeficiency virus Gag antigen.

7. The lentiviral vector particle of claim 6 , wherein the Gag antigen is a GagΔmyr protein devoid of myristylation.

8. The lentiviral vector particle of claim 1 , wherein the functional lentiviral DNA flap sequence is an HIV-1 DNA flap sequence.

9. The lentiviral vector particle of claim 1 , wherein the lentiviral vector particle comprises a nucleic acid comprising an LTR devoid of the enhancer of the U3 region.

10. The lentiviral vector particle of claim 1 , wherein the lentiviral vector particle encodes at least one human immunodeficiency virus Nef, Tat, Rev, or Pol antigen.

11. The lentiviral vector particle of claim 1 , wherein the lentiviral vector particle is a human immunodeficiency virus vector particle.

12. The lentiviral vector particle of claim 2 , wherein the lentiviral vector particle encodes at least one human immunodeficiency virus Gag antigen.

13. The lentiviral vector particle of claim 3 , wherein the lentiviral vector particle encodes at least one human immunodeficiency virus Gag antigen.

14. The lentiviral vector particle of claim 4 , wherein the lentiviral vector particle encodes at least one human immunodeficiency virus Gag antigen.

15. The lentiviral vector particle of claim 5 , wherein the lentiviral vector particle encodes at least one human immunodeficiency virus Gag antigen.

16. The lentiviral vector particle of claim 2 , wherein the functional lentiviral DNA flap sequence is an HIV-1 DNA flap sequence.

17. The lentiviral vector particle of claim 3 , wherein the functional lentiviral DNA flap sequence is an HIV-1 DNA flap sequence.

18. The lentiviral vector particle of claim 4 , wherein the functional lentiviral DNA flap sequence is an HIV-1 DNA flap sequence.

19. The lentiviral vector particle of claim 5 , wherein the functional lentiviral DNA flap sequence is an HIV-1 DNA flap sequence.

20. A method for priming and subsequently boosting an immune response in a mammalian host comprising administering the lentiviral vector particle of claim 1 at different times to a mammalian host.

21. A method for inducing an immune response in a human comprising administering the lentiviral vector particle of claim 1 to a human.

22. The method of claim 21 , wherein the human is infected with a human immunodeficiency virus.

Assignees

• Pasteur Institut
• Centre Nat Rech Scient
• Theravectys

Inventors

• Charneau Pierre
• Beignon Anne-Sophie
• Coutant Frederic Philippe
• Courbeyrette Karine

Classifications

• A61P31/12

  Antivirals · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P33/00

  Antiparasitic agents · CPC title

• A61P31/18

  for HIV · CPC title